Correction of feline arylsulphatase B deficiency (mucopolysaccharidosis VI) by bone marrow transplantation. 1984

P W Gasper, and M A Thrall, and D A Wenger, and D W Macy, and L Ham, and R E Dornsife, and K McBiles, and S L Quackenbush, and M L Kesel, and E L Gillette

Feline and human mucopolysaccharidosis VI (MPS VI or Maroteaux-Lamy syndrome) are inherited autosomal recessive deficiencies of lysosomal enzyme arylsulphatase B. Affected cats and children exhibit lesions caused by incompetent degradation, retinal atrophy and excessive urinary excretion of dermatan facial dysmorphia, corneal stromal opacities, leukocyte granulation, retinal atrophy and excessive urinary excretion of dermatan sulphate--and usually die before adulthood. Most attempts to treat humans affected with MPS VI or other mucopolysaccharidoses have been ineffective or logistically prohibitive, but allogeneic bone marrow transplantation (BMT) offers promise for cure of certain inborn errors of metabolism. Engraftment of normal donor marrow may endow the enzyme-deficient recipient with a continuous source of enzyme-competent blood cells and tissue macrophages to facilitate degradation of stored substrate and to prevent genesis of further malformations. To test this hypothesis, we performed allogeneic BMT in a 2-year-old male Siamese cat with advanced MPS VI. Here we describe BMT-induced correction of this hereditary enzyme deficiency.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D008297 Male Males
D009083 Mucopolysaccharidoses Group of lysosomal storage diseases each caused by an inherited deficiency of an enzyme involved in the degradation of glycosaminoglycans (mucopolysaccharides). The diseases are progressive and often display a wide spectrum of clinical severity within one enzyme deficiency. Mucopolysaccharidosis
D009087 Mucopolysaccharidosis VI Mucopolysaccharidosis with excessive CHONDROITIN SULFATE B in urine, characterized by dwarfism and deafness. It is caused by a deficiency of N-ACETYLGALACTOSAMINE-4-SULFATASE (arylsulfatase B). Maroteaux-Lamy Syndrome,Polydystrophic Dwarfism,ARSB Deficiency,Arylsulfatase B Deficiency,Mucopolysaccharidosis 6,Mucopolysaccharidosis Type 6,Mucopolysaccharidosis Type VI,N-Acetylgalactosamine-4-Sulfatase Deficiency,ARSB Deficiencies,Arylsulfatase B Deficiencies,Deficiencies, ARSB,Deficiencies, Arylsulfatase B,Deficiencies, N-Acetylgalactosamine-4-Sulfatase,Deficiency, ARSB,Deficiency, Arylsulfatase B,Deficiency, N-Acetylgalactosamine-4-Sulfatase,Dwarfism, Polydystrophic,Maroteaux Lamy Syndrome,N-Acetylgalactosamine-4-Sulfatase Deficiencies,Syndrome, Maroteaux-Lamy,Type 6, Mucopolysaccharidosis,Type VI, Mucopolysaccharidosis
D010315 Particle Accelerators Devices which accelerate electrically charged atomic or subatomic particles, such as electrons, protons or ions, to high velocities so they have high kinetic energy. Betatrons,Linear Accelerators,Accelerator, Linear,Accelerator, Particle,Accelerators, Linear,Accelerators, Particle,Betatron,Linear Accelerator,Particle Accelerator
D002371 Cat Diseases Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used. Feline Diseases,Cat Disease,Disease, Cat,Disease, Feline,Diseases, Cat,Diseases, Feline,Feline Disease
D002415 Cats The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801) Felis catus,Felis domesticus,Domestic Cats,Felis domestica,Felis sylvestris catus,Cat,Cat, Domestic,Cats, Domestic,Domestic Cat
D002803 Chondro-4-Sulfatase An enzyme from the sulfuric ester hydrolase class that breaks down one of the products of the chondroitin lyase II reaction. EC 3.1.6.9. Chondro 4 Sulfatase
D006025 Glycosaminoglycans Heteropolysaccharides which contain an N-acetylated hexosamine in a characteristic repeating disaccharide unit. The repeating structure of each disaccharide involves alternate 1,4- and 1,3-linkages consisting of either N-acetylglucosamine (see ACETYLGLUCOSAMINE) or N-acetylgalactosamine (see ACETYLGALACTOSAMINE). Glycosaminoglycan,Mucopolysaccharides

Related Publications

P W Gasper, and M A Thrall, and D A Wenger, and D W Macy, and L Ham, and R E Dornsife, and K McBiles, and S L Quackenbush, and M L Kesel, and E L Gillette
July 2007, Molecular genetics and metabolism,
P W Gasper, and M A Thrall, and D A Wenger, and D W Macy, and L Ham, and R E Dornsife, and K McBiles, and S L Quackenbush, and M L Kesel, and E L Gillette
August 1997, European journal of immunology,
P W Gasper, and M A Thrall, and D A Wenger, and D W Macy, and L Ham, and R E Dornsife, and K McBiles, and S L Quackenbush, and M L Kesel, and E L Gillette
January 1981, Enzyme,
P W Gasper, and M A Thrall, and D A Wenger, and D W Macy, and L Ham, and R E Dornsife, and K McBiles, and S L Quackenbush, and M L Kesel, and E L Gillette
June 1991, Bone marrow transplantation,
P W Gasper, and M A Thrall, and D A Wenger, and D W Macy, and L Ham, and R E Dornsife, and K McBiles, and S L Quackenbush, and M L Kesel, and E L Gillette
June 1991, The Biochemical journal,
P W Gasper, and M A Thrall, and D A Wenger, and D W Macy, and L Ham, and R E Dornsife, and K McBiles, and S L Quackenbush, and M L Kesel, and E L Gillette
March 1979, Transplantation proceedings,
P W Gasper, and M A Thrall, and D A Wenger, and D W Macy, and L Ham, and R E Dornsife, and K McBiles, and S L Quackenbush, and M L Kesel, and E L Gillette
October 2015, The Indian journal of medical research,
P W Gasper, and M A Thrall, and D A Wenger, and D W Macy, and L Ham, and R E Dornsife, and K McBiles, and S L Quackenbush, and M L Kesel, and E L Gillette
September 1997, Pediatric radiology,
P W Gasper, and M A Thrall, and D A Wenger, and D W Macy, and L Ham, and R E Dornsife, and K McBiles, and S L Quackenbush, and M L Kesel, and E L Gillette
December 2002, Blood,
P W Gasper, and M A Thrall, and D A Wenger, and D W Macy, and L Ham, and R E Dornsife, and K McBiles, and S L Quackenbush, and M L Kesel, and E L Gillette
January 1991, Human gene therapy,
Copied contents to your clipboard!